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Abstract. Ertapenem is an antibiotic commonly used to treat a broad spectrum of infections, which is part of a broader class of antibiotics called carbapenem. Unlike other carbapenems, ertapenem has a longer half-life and
thus only has to be administered once a day. A physiologically-based pharmacokinetic (PBPK) model was developed to investigate the uptake, distribution,
and elimination of ertapenem following a single one gram dose. PBPK modeling incorporates known physiological parameters such as body weight, organ
volumes, and blood flow rates in particular tissues. Furthermore, ertapenem
is highly bound in human blood plasma; therefore, nonlinear binding is incorporated in the model since only the free portion of the drug can saturate
tissues and, hence, is the only portion of the drug considered to be medicinally effective. Parameters in the model were estimated using a least squares
inverse problem formulation with published data for blood concentrations of
ertapenem for normal height, normal weight males. Finally, an uncertainty
analysis of the parameter estimation and model predictions is presented.
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1. Introduction. Ertapenem is a once-a-day antibiotic commonly used to treat
community-acquired and mixed infections [15, 17]. It is part of the class of antimicrobials called carbapenems, which is one of the distinct classes of the β-lactams;
β-lactams are used to treat serious infections [23]. Carbapenems are regarded as
the most potent class of β-lactams and have the widest spectrum of antimicrobial
activity against both gram-positive and gram-negative bacteria [8, 23].
Imipenem and meropenem, which are the other two carbapenems, have an elimination half-life of approximately one hour and are less protein bound; they must
be administered several times a day [17, 23]. They also are active against nonfermentative gram-negative bacilli and nosocomial infections [12]. Unlike imipenem
and meropenem, ertapenem has a half-life of approximately four to five hours due
to high protein binding; approximately 94% of ertapenem is protein bound [8, 23].
This allows ertepenem to be administered just once a day as an intravenous infusion in adult patients [12, 14, 15, 17, 23]. Ertapenem has only limited activity
against non-fermentative gram-negative bacilli but is well-suited for use against
community-acquired infections [12, 14].
Ertapenem is indicated for use against a wide variety of infections. In the European Union, ertapenem is licensed for the treatment of intra-abdominal and gynecological infections as well as community-acquired pneumonia. In the United States,
it is also licensed for the treatment of skin infections and for complicated urinary
tract infections [12, 14, 23]. Other uses include treatment of acute pelvic infections
and pediatric patients with complicated bacterial infections [12]. Ertapenem may
be administered either by intravenous or intramuscular route [12, 23].
Others models for ertapenem have previously appeared in the literature [7, 15].
Our approach will be different as we will use a multi-compartment model based on
physiologically-based pharmacokinetic framework. Although it is not the focus of
this article, this approach will allow for examination of individuals with different
physiological characteristics, such as body mass index, in the future.
In this article, we seek to investigate the uptake, distribution, and elimination
of ertapenem following a single one gram intravenous dose. We begin in Section
2 with the development of a physiologically-based pharmacokinetic (PBPK) model
from mass balance techniques and incorporate specifics related to the dosing and
behavior of ertapenem. In Section 3, inverse problems are performed to estimate the
unknown parameters in the model. Numerical simulations are carried out for a normal weight, normal height male and compared to clinical data. Uncertainty analysis
is investigated using a bootstrapping technique in Section 4. We will conclude with
some final remarks in Section 5.
2. Model structure and assumptions. Pharmacokinetic modeling seeks to examine factors that affect absorption, distribution, metabolism, and excretion [3].
PBPK modeling incorporates known physiological parameters such as body weight,
organ volumes, and blood flow rates in particular tissues.
In this initial model for ertapenem, we will focus our attention on the tissues and
organs most affected by the drug. The PBPK model has separate compartments
representing the blood (Bl), kidney (K), adipose or fat (F ), the gut (G), and other
aggregated tissues (OT ) as well as the urine (u) and the feces (f ); the kidney and
gut have been included so that urine and feces excretion can be considered whereas
the adipose compartment is included so the effects of differing body weight can be
examined in a subsequent paper. Urine and feces excretion are considered to occur

PBPK MODEL FOR ERTAPENEM

121

at linear rates and are represented by ku CK and kf CG , respectively, where ku and
kf are the first-order linear rate constants for excretion and CK and CG represent
the concentrations of ertapenem in the kidney and gut. Since hepatic metabolism
only plays a minor role in the elimination of ertapenem [17], it is not included in
this model. Intravenous (IV) dosing is described by infusion directly into the blood
compartment. See Figure 1 for a schematic of the model.

Infusion

Adipose (Fat)

Kidney

Urine

Blood

Gut

Feces

Other Tissues

Figure 1. Schematic Representation of Compartment Model
Ertapenem is highly bound to human plasma proteins. Only the free, unbound
portion of the drug actually saturates the tissues and can be excreted [3]. Moreover, since only the free, or unbound, concentration of the drug is considered to
be medicinally effective, we chose to examine both the total concentration and the
free concentration in the blood. The total blood concentration, CBl , is comprised
of both the free concentration (CBf ) and the bound concentration (CBound ),
CBl = CBf + CBound .
Ertapenem exhibits nonlinear binding [10]; therefore, the bound concentration in
the blood can be modeled using a nonlinear Michaelis-Menten equation
Bm CBf
,
CBound =
Kd + CBf
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where Bm is the density of binding sites and Kd is the dissociation constant [11, 19].
By substituting the equation for the bound concentration into the equation for the
total concentration, we have
Bm CBf
CBl = CBf +
.
(1)
Kd + CBf
Thus, the total and free concentrations can be studied without directly calculating the bound concentration. By algebraic manipulation, we obtain the following
equation for the free concentration:
p
CBl − Bm − Kd + (Bm + Kd − CBl )2 + 4Kd CBl
.
(2)
CBf =
2
This equation gives the free concentration in terms of CBl , Bm , and Kd .
According to work by Merck & Co., “In healthy young adults, the protein binding
of ertapenem decreases as plasma concentrations increase, from approximately 95%
bound at an approximate plasma concentration of < 100 micrograms (mcg)/mL to
approximately 85% bound at an approximate plasma concentration of 300 mcg/mL”
[10]. Thus, ertapenem is not flowing quickly out of the blood into other tissues
because of the high percentage that is bound; this also impacts how quickly the
drug begins to be excreted from the body. This concept impacted our decision
to implement an infusion coefficient, α, into the model. Instead of assuming that
during the infusion that the outflow from the blood compartment was the entire
free portion of the drug, we assumed that only a fraction of the free concentration
was leaving the blood; thus, during infusion, the blood flow rate from the blood
into each tissue compartment was multiplied by a constant value between 0 and 1,
which is referred to as αI , and after infusion, the infusion coefficient α is set equal
to 1. Thus, the infusion constant α is defined by

αI , 0 < t ≤ TI
α=
.
1, TI < t < 24
Since ertapenem has a longer half-life than most antibiotics and is being given
during a short infusion time, the overall process of uptake and excretion is slow.
Thus, since not all physiological characteristics can be taken into account, one way
to include these components in our model was to assume that none of the drug was
excreted via urine or feces during the infusion. Thus, ku and kf were set to zero
during the infusion.
All subjects were considered to be male, and the average height and weight for
normal males were used (See Table 1) [25]. The compartment volumes (given in
mL) were based on body height and body weight; the calculations for VBl and VK
were obtained from [22] whereas the one for VF was from [13] and the VG was from
[18]. The equations for compartment volumes are given by
VBl
VK
VF
VG

13.1(BH ∗ 100) + 18.05(BW ) − 480
0.5723
= 15.4 + 2.04(BW ) + 51.8(BH)2


BW
=
1.36 ∗
− 42 ∗ 1000
BH
= 0.0171 ∗ (BW ) ∗ 1000,
=

where BW denotes the total body mass and BH is the body height. The International Life Sciences Institute provides a table of tissue densities in humans. For
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Table 1. Parameter Values Obtained from Literature
Parameter
BW
BH
QT otal
QF
QK
QG

Value
72
1.75
235 ∗ (BW )0.71 ∗ 60
0.052 ∗ QT otal
0.19 ∗ QT otal
0.17 ∗ QT otal

Units
kg
m
mL/hr
mL/hr
mL/hr
mL/hr

Reference
[25]
[25]
[5]
[18]
[18]
[18]

most soft tissues the value falls between 0.95 and 1.05; only in a few cases are tissue
densities outside of the range 0.9 to 1.1 [9]. Thus, we assume total volume of the
body was equal to body weight, with a only a change of units needed.
1L
1kg
.
∗
BW = V olume ∗
1L
103 mL
Then, we define VOT as the fraction of the total BW not included in the blood,
adipose, kidney, or gut compartments
VOT = BW ∗ 1000 − (VBl + VF + VK + VG ).
The total rate flow in the body was calculated using the subject’s body weight
[5],
QT otal = 235 ∗ (BW )0.71 ∗ 60.
The flow rates for the adipose, kidney, and gut compartments were a percentage of
QT otal , which are given in Table 1 [18]. QOT was defined as the fraction of QT otal
not included in the adipose, kidney, or gut compartments
QOT = QT otal − (QF + QK + QG ).
The venous-equilibrium model was used for each tissue compartment, which
means that in the time that it takes the blood to perfuse the tissue, the drug
is able to achieve an equilibrium concentration between the blood and the tissue
[3]. Therefore, it was assumed that the concentration in the venous blood leaving
the compartment was at equilibrium with the concentration in the compartment,
with Pi being the equilibrium partition coefficient for tissue i:
Ci
Cvenous =
.
Pi
Thus, this model requires partition coefficients of various tissues and blood. Partition coefficients for the individual tissue compartments represent the tissue’s solubility; they determine the portion of the concentration that can flow from each
tissue back into the blood. For example, PF =1.95 means 1 mL of adipose tissue
can hold 1.95 times as much ertapenem as 1 mL of blood. The partition coefficients
were obtained by using an algorithm introduced by Poulin and Krishnan [20, 21].
The algorithm is based on n-octanol:water (Ko/w) partition coefficient data. It assumes that the sum of the solubility of a chemical in neutral lipids, phospholipids,
and water in a particular tissue or blood is equal to the solubility of the chemical
in the tissue or blood, respectively. The equation includes both physiological and
drug specific parameters and is given by
[So ∗ Nt ] + [(Sw ∗ 0.7Pt ) + (So ∗ 0.3Pt )] + [Sw ∗ Wt ]
,
Pt =
[So ∗ Nb ] + [(Sw ∗ 0.7Pb ) + (So ∗ 0.3Pb )] + [Sw ∗ Wb ]
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where Sw is the solubility of the chemical in water and S0 is the solubility of the
chemical in n-octanol [21]. Nt , Pt , and Wt are the fractions of the tissue volume that
are neutral lipids, phospholipids, and water, respectively; whereas, Nb , Pb , and Wb
are the fractions of the blood volume that are neutral lipids, phosophilipids, and water. For ertapenem, Sw =0.069230349 mol/m3 and S0 = Kow ∗ Sw where Kow =1.66
is the octanol-water partition coefficient of ertapenem [6]. The muscle:blood partition coefficient was used for the other tissue:blood partition coefficient. The values
calculated for the partition coefficients in this model are given in Table 2.
Table 2. Calculated Partition Coefficients
Parameter
PF
PK
PG
POT

Value
1.95
1.05
0.90
1.01

During the infusion, the rate of infusion is given by
 D
TI , 0 ≤ t ≤ TI ,
RI =
0,
t > TI

(3)

where D is the dosage and TI is the length of infusion. The model is described by
the following system of differential equations:


dCF
CF
VF
= QF αCBf −
dt
PF


CK
dCK
= QK αCBf −
VK
− ku C K
dt
PK


CG
dCG
= QG αCBf −
VG
− kf C G
dt
PG


COT
dCOT
= QOT αCBf −
(4)
VOT
dt
POT
dCBl
CF
CK
CG
COT
VBl
= QF
+ QK
+ QG
+ QOT
− αQT otal CBf + RI
dt
PF
PK
PG
POT
dAu
= ku CK
dt
dAf
= kf CG ,
dt
where CBf and RI are given by equations (2) and (3), respectively. We assumed
there were no background levels of ertapenem in the body, so all initial conditions
were zero. The variables and parameters for the model are summarized in Table 3.
3. Parameter estimation. The model given by Equations (2) - (4) contains five
unknown parameters (Kd , Bm , αI , ku , and kf ) which are estimated in this section.
Mean plasma concentrations of total and free (unbound) ertapenem at corresponding time points were approximated from graphical data given for healthy adult
subjects in Nix et. al. [17] using an extraction program [24] and are given in Table
4. The Nix data [17] corresponded well to the data in [10], but we chose to use the
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Table 3. Definitions of Model Variables and Parameters
Symbol
Ci
CBf
Au
Af
Vi
Qi
t
Pi
BW
BH
α
RI
D
TI
ku
kf
Bm
Kd

Description
Concentration of ertapenem in tissue i
Concentration of free ertapenem in the blood
Amount of ertapenem in urine
Amount of ertapenem in feces
Volume of tissue i
Flow Rate in tissue i
Time
Blood partition coefficient of tissue i
Body Weight
Body Height
Infusion Coefficient
Rate of Infusion
Dose
Length of Infusion
First-order rate constant of urine excretion
First-order rate constant of feces excretion
Blood receptor constant
Dissociation constant

Units
mcg/mL
mcg/mL
mcg
mcg
mL
mL/hr
hr
dimensionless
kg
m
dimensionless
mcg/hr
mcg
hr
mL/hr
mL/hr
mcg/mL
mcg/mL

data from Nix as both total and free concentrations were available in this reference.
We split the parameter estimation problem into two parts: 1) estimation of Kd and
Bm , and 2) estimation of αI , ku , and kf . Parameters Kd and Bm only appear in the
relationship between the free and total concentration; therefore, it is not necessary
to use the entire model to determine these parameters. Moreover, if one performs
this estimation separate from the entire model, one can use this relationship in future studies (depending on the focus of the study). We note that similar, yet slightly
different, parameter estimates are found if one performs a single optimization problem; however, the two-part optimization problem produces a better estimate for the
relationship between the free and total concentration. Since free concentration is
important in determining the medical effectiveness of the antibiotic, we choose to
implement the two-part optimization problem.
Table 4. Clinical Data for the Total and Free Concentrations of
Ertapenem [17]

Time (tj )
(hr)
0.5
4
6
8
12
18

Total Concentration
(CBl (tj ) ≡ y1j )
(mcg/mL)
160.30
50.57
30.47
20.56
10.47
3.70

Free Concentration
(CBf (tj ) ≡ y2j )
(mcg/mL)
15.48
2.70
1.58
1.10
0.42
0.15
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3.1. Estimation of Kd and Bm . In Section 2, we introduced two equivalent relationships for the total concentration of ertapenem in the blood, CBl , and the free
or unbound concentration, CBf , with unknown parameters Km and Bd . Equation
(1) defines the total concentration as a function of the free concentration dependent
on the parameter q = [Kd , Bm ], i.e. CBl (t) = f1 (t, q), where
f1 (t, q) ≡ f1 (CBf (t), q) = CBf (t) +

Bm CBf (t)
.
Kd + CBf (t)

Similarly, Equation (2) defines the free concentration as a function of the total
concentration, i.e. CBf (t) = f2 (t, q) where
f2 (t, q) ≡ f2 (CBl (t), q)
=

CBl (t) − Bm − Kd +

p

(Bm + Kd − CBl (t))2 + 4Kd CBl (t)
.
2

We assume the data in Table 4 is a realization y∗j of the statistical model
Y∗j = f∗ (tj , q0 )(1 + Ẽ∗j ),
where q0 is assumed to be the vector of “true” parameter values for the relationship
between CBl and CBf and Ẽ∗j is measurement error which is identically distributed
with constant variance, i.e. E(Ẽ∗j ) = 0 and Var(Ẽ∗j ) = σ02 . Thus, in the estimation
problem for Kd and Bm , we seek an estimator q,
q = arg min
q∈Q

N
X

f1−2 (tj , q)[Y1j − f1 (tj , q)]2 + f2−2 (tj , q)[Y2j − f2 (tj , q)]2



j=1

with corresponding estimate

2 
2 !
N
X
y1j − f1 (tj , q)
y2j − f2 (tj , q)
q̂ = arg min
+
,
q∈Q
f1 (tj , q)
f2 (tj , q)
j=1
where Q is the set of admissible parameter values and N = 6 is the number of time
steps for which we have data.
In order to insure all parameter values were nonnegative throughout the estimation process, we use a ln − exp transformation in the inverse problem. The
parameter values are initially transformed by taking the natural logarithm of each
value and then the Nelder-Mead simplex method is employed using the fminsearch
function in MATLAB [16] to find the optimal values for ln q, where q is the parameter value. Finally, the parameter values are transformed back by taking the
exponential. The initial guesses for these parameters were ln (Kd0 ) = ln (15) and
ln (Bm0 ) = ln (260). The rank of the Fisher Information Matrix, F = χT W χ, was
used to determine that the parameters were identifiable [4] where the inverse of W
is a matrix defined by
W −1 = diag(f12 (t1 , q), ..., f12 (tN , q), f22 (t1 , q), ..., f22 (tN , q)),
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χ(q) = 






∂f1 (t1 ,q)
∂Km

..
.

∂f1 (t1 ,q)
∂Bd

..
.

∂f1 (tN ,q)
∂Km
∂f2 (t1 ,q)
∂Km

∂f1 (tN ,q)
∂Bd
∂f2 (t1 ,q)
∂Bd

∂f2 (tN ,q)
∂Km

∂f2 (tN ,q)
∂Bd

..
.

..
.
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Figure 2 shows the approximation for CBf = f2 (CBl (t), q) using the estimated
optimal values Bm = 243.28 mcg/mL and Kd = 10.88 mcg/mL. In Section 4, we
examine the uncertainty in the parameter estimates and the propagation of this
uncertainty into the model using a bootstrapping method.
16
14

Free Concentration CBf as a Function of Total Concentration CBl
Data
Approx

CBf (mcg/mL)

12
10
8
6
4
2
0
0

20

40

60

80
100
CBl (mcg/mL)

120

140

160

Figure 2. Free concentration as a function of total concentration
using optimal values for Bm and Kd .

3.2. Estimation of αI , ku , and kf . In the previous subsection, we were able to
estimate Kd and Bm separately from the model, since these parameters rely strictly
on the relationship between the free and total concentrations. To estimate αI , ku ,
and kf , we must use the entire model given by Equations (2) - (4). As discussed in
Section 2, since we assume that during infusion a fraction of the free concentration
is leaving the blood, the infusion constant, α, is defined by

αI , 0 < t ≤ TI
α=
,
1, TI < t < 24
where 0 < αI < 1. All other times, we assume the entire free concentration of
ertapenem will flow through the body. Therefore, αI is the parameter we wish to
estimate. The parameters αI , ku , and kf were found to be structurally identifiable
using the differential algebra approach to identifiability as outlined by Bellu et. al.
[2].
The goal of the estimation problem is to find parameter values such that the
model is a good approximation of the measured concentrations in the blood (CBl
and CBf ) as well as the measured excretion; therefore, in addition to the data in
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Free Concentration

Total Concentration
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180

Model
Nix Data
Merck Data

160

100

Bf
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8
6
4
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2

20
0
0

12
(mcg/mL)

120
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CBl (mcg/mL)

140
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14

5
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time(hr)
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(a) Total Concentration

0
0

5

10

time(hr)

15

20

(b) Free Concentration

Figure 3. Simulation of Equations (2) - (4) using optimal parameter values given in Sections 3.1 and 3.2. Plot (A) illustrates the
total concentration CBl . Plot (B) illustrates the free concentration
CBf .
Table 4, we also use the fact that 80% of the ertapenem dose is typically excreted
in the urine within a 24-hour period [10]. As we did in the previous section, we
assume the data (including excretion of 80%) is a realization y of a statistical model
Y = g(t, q0 )(1 + Ẽ)
where q = [αI , ku , kf ], the measurement error Ẽj is identically distributed with
constant variance, and g(t, q0 ) is the measured, or observed, part of the model at
the “true” parameter q0 . We note that y = [y1j , y2j , 0.8]T , j = 1, ...N where y∗j is
the data given in Table 4, and the observed part of the solution is
g(t, q) = [CBl (t, q), CBf (t, q), Au (t)]T .
Since we only have data for CBl and CBf at times tj = 0.5, 4, 6, 8, 12, 18 and Au at
time 24, we only consider the observed part of the solution at these time points in
the optimization problem. Therefore, we seek an estimator q̂,

2
N 
X
y1j − CBl (tj , q))
q̂ = arg min
q∈Q 
CBl (tj , q)
j=1

2 
2
N 
X
y2j − CBf (tj , q))
0.8 − Au (24) 
+
.
+

CBf (tj , q)
Au (24)
j=1
In the parameter estimation problem for αI , ku and kf , we set Kd and Bm
equal to the optimal values given in Section 3.1. We then use fminsearch and the
transformation technique discussed in Section 3.1 to obtain the estimated values
αI = 0.32, ku = 68588 mL/hr and kf = 9639 mL/hr. Figure 3 shows the simulation
of the model in Equations (2) - (4) using the optimal parameter values with the
data; additional total concentration data from Merck & Co. [10] was also plotted
in order to compare to data that was not used in the optimization. The comparison
between concentration values from the Nix study (Table 4) and the model is given
in Table 5; furthermore, the urine excretion is estimated as approximately 80%,
the same as the clinical average. The model has an average 6% relative point error
when compared to the data.
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Table 5. Comparison of Model Output and Data
tj
(hours)
0.5
4
6
8
12
18

CBl
(mcg/mL)
Data Model
160.30 157.77
50.57 44.21
30.47 30.55
20.56 21.42
10.47 10.62
3.70
3.71

CBf
(mcg/mL)
Data Model
15.48 15.36
2.70
2.27
1.58
1.48
1.10
1.00
0.42
0.47
0.15
0.16

4. Uncertainty analysis. Due to the small number of data points, asymptotic
theory is not appropriate for estimating the uncertainty in the parameter estimates;
therefore, in this section, we use a popular bootstrapping technique to investigate
the uncertainty in the parameter estimation and how this uncertainty propagates
through the model. We construct a family of samples or simulated data using
the residuals obtained from the estimates in Table 5. Using the generated sample
data, we obtain estimates for the parameters and model simulations using these
estimates. The following algorithm is a modified version of the bootstrapping algorithm in Banks et. al. [1] used to determine a distribution of parameter values and
corresponding uncertainty in model simulations using 1000 constructed samples.
1. First, estimate optimal parameter values for Bm and Kd using the data in
Table 4 and the method defined in Section 3.1.
2. Substitute optimal parameter values Bm and Kd found in Step 1 in the model
given by Equations (2) - (4). Then estimate αI , kf , and ku using the methods
outlined in Section 3.2.
0
3. Let θ0 = [Bm
, Kd0 , αI0 , kf0 , ku0 ] be the vector of optimal parameter values found
in steps 1 and 2. Define the set


y1j − CBl (tj , θ0 ) y2j − CBf (tj , θ0 ) 0.8 − Au (24, θ0 )
S=
,
,
, j = 1, ..., N
CBl (tj , θ0 )
CBf (tj , θ0 )
Au (24, θ0 )
to be the set of 13 standardized residuals.
4. From the set S = {s1 , s2 , ..., s13 }, form a bootstrapping sample Sb = {sn1 ,
sn2 , ..., sn13 } by using random sampling with replacement from the set S.
5. Create a sample data set y n using Sb :

 CBl (tj , θ0 ) + CBl (tj , θ0 )snk , k = 1, ..., 6, j = 1, ...N
n
CBf (tj , θ0 ) + CBf (tj , θ0 )snk , k = 7, ..., 12, j = 1, ..., N
y =

Au (24, θ0 ) + Au (24, θ0 )snk ,
k = 13.
6. Obtain a new estimate θ0n :
n
• First estimate Bm
and Kdn using data ykn , k = 1, ..., 12 and the method
defined in Section 3.1.
n
• Then substituting Bm
and Kdn in the model given by Equations (2) - (4),
n
n
estimate αI , kf , and kun using the methods outlined in Section 3.2 and
the data y n .
7. Simulate the model using θ0n .
8. Set n = n + 1 and repeat steps 4-7 until n=1000.
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We calculate 90% confidence intervals for the parameters using the formula
[q̂ − t0.05 (SE), q̂ + t0.05 (SE)].
with critical value t0.05 from the student’s t distribution t2N −p with 2N − p degrees
of freedom for Bm and Kd and t2N +1−p with 2N + 1 − p degrees of freedom for
αI , ku and kf (N = 6, p = 2) [1]. Table 6 gives the parameter estimates and
confidence intervals using the bootstrap method. There is a lot of variability in
the confidence intervals, especially for ku and kf ; however, the variability in the
parameter estimates do not generate a significant amount of variability in model
predictions for the concentration of ertapenem in the blood as shown in Figure 4
(grey shaded region). Moreover, the mean amount of ertapenem excreted in the
urine across the 1000 sample data sets is 81% of the dose with standard deviation
of 0.07%. Finally, we can use the statistical model given in Section 3.2,
Y = g(t, q0 )(1 + Ẽ),
to estimate a 95% confidence interval for the total concentration of ertapenem using
the model in Equations (2) - (4), optimal parameter values found in Sections 3.1
and 3.2, and assuming Ẽj is identically distributed with constant variance Var(Ẽ) =
σ02 ≈ σ̂ 2 where

2
N 
X
y1j − CBl (t, q)
1

σ̂ 2 =
2N + 1 − p j=1
CBl (t, q)

2 
2
N 
X
0.8 − Au (24) 
y2j − CBf (t, q))
+
+
.
CBf (t, q)
Au (24)
j=1
Figure 5 shows the data (blue stars) for the total concentration of ertapenem in the
blood as a function of time, corresponding model simulation with optimal parameters (green line), uncertainty in model simulations due to distribution of parameter
estimations (light grey area), and 95% confidence interval in solution assuming a
statistical model as above (black dashed line).
Table 6. Estimates and Error Bounds for All Parameters using
Bootstrapping
q̂
Bm ( mcg
mL )
Kd ( mcg
mL )
αI (unitless)
ku ( mL
hr )
kf ( mL
hr )

Est
SE
90% CI
252.53 48.06 [165.42, 339.64]
11.35
2.60
[6.65, 16.05]
0.29
0.16
[0.01,0.58]
71405 15214 [43830 ,98981]
8875
3837
[1921, 15829]

5. Discussion and conclusions. In this paper, we developed a PBPK model for a
single gram dose of the antibiotic ertapenem administered intravenously. Ertapenem
is a highly bound antibiotic; therefore, we chose to consider the free or unbound
concentration separately from the total concentration in the blood. In the future this
will allow us to test the effect of varying physiological parameters on the medicinally
effective portion of the antibiotic. We fitted the model to published clinical data
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(b) Free Concentration

Figure 4. Total Concentration CBl (A) and Free Concentration
CBf (B): Propagation of uncertainty of parameter estimates into
the model using the bootstrapping algorithm described in Section
4.

Figure 5. This figure shows the data (blue stars) for the total
concentration of ertapenem in the blood as a function of time, the
corresponding model simulation with optimal parameters (green
line), uncertainty in model simulations due to distribution of parameter estimations (light grey area), and 95% confidence interval
in solution assuming a statistical model as above (black dashed
line).
producing a model fit with an average of only 6% relative point error when compared
to the data. Furthermore, we examined the effect of uncertainty in the parameter
estimations and the consequence of propagating this uncertainty into the model
prediction. We note that all data points, which are averages from the Nix study
[17], lie within a 95% confidence interval of the solution curve. If a large number of
individual measurements were taken, one can assume that 95% of the data points
would lie within the given confidence interval.
The standard PBPK modeling techniques used in the development of the model
for ertapenem can be modified and used for other antibiotics. Furthermore, the
separation of the free and total concentration in the modeling process allows one to
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examine potential cases in which the free concentration may fall below the minimum
inhibitory concentration and thus allow for the potential development of resistant
bacteria. In a future paper, we use this model to examine the potential effects
of varying parameters such as weight, height or gender on this minimum level of
free concentration; this would allow us to better predict what the most effective
dosing might be, which would hopefully then produce the most timely healing of
the infection and minimize antibiotic resistance.
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